萨瑞普塔治疗
SRPT
17.10
-0.69
-3.88%
萨瑞普塔治疗
US · SRPT
#2853 按市值排名
上市于 1970
17.10
-0.69
-3.88%
实时 - 追踪5344个代码 - 心跳于482秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例上升了0.2个百分点。
机构持股
- 机构持股比例
- 102.80% +0.20pp
- 机构数量
- 384 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund73.81%
Hedge Fund18.27%
Public Company7.24%
Individual/Insider4.78%
Private Company1.51%
Government Pension Fund1.11%
VC/PE Fund0.46%
Insurance Company0.30%
主要股东 截至 2026-06-30
BlackRock
17.98% · 18.99M 股
State Street Global Advisors
8.44% · 8.92M 股
Vanguard Portfolio Management, LLC
7.93% · 8.38M 股
Vanguard Capital Management, LLC
5.01% · 5.29M 股
Two Sigma Investments, LP
4.35% · 4.60M 股
First Trust Advisors L.P.
4.13% · 4.37M 股
AQR Capital Management
4.04% · 4.27M 股
Richard Barry
3.05% · 3.22M 股
Geode Capital Management, LLC
2.62% · 2.77M 股
Erste Asset Management GmbH
2.43% · 2.57M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 26次买入 · 24次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Richard Barry | Independent Director | 3.05% |
| Michael Chambers | Independent Director | 0.46% |
| Douglas Ingram | Chief Executive Officer | 0.37% |
| M. Behrens Wilsey | Independent Chairwoman | 0.20% |
| Louise Rodino-Klapac | Executive VP, Chief Scientific Officer and Head of Research & Development | 0.19% |
| Ian Estepan | Chief Financial Officer | 0.17% |
| Ryan Wong | Chief Financial Officer | 0.12% |
| Cristin Rothfuss | -- | 0.11% |
| Claude Nicaise | Independent Director | 0.03% |
| Hans Wigzell | Chairman of Corporate Strategy Board & Independent Non-Employee Director | 0.02% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-03 | Louise Rodino-Klapac | Executive VP, Chief Scientific Officer and Head of Research & Development | Sale to Issuer | -21,423 | $22.22 |
| 2026-09-03 | Ian Estepan | Chief Financial Officer | Sale to Issuer | -24,799 | $22.22 |
| 2026-09-03 | Cristin Rothfuss | -- | Sale to Issuer | -22,025 | $22.22 |
| 2026-09-03 | Ryan Wong | Chief Financial Officer | Sale to Issuer | -13,272 | $22.22 |
| 2026-07-27 | Michael Severino | Chief Executive Officer | Other Acquisition | +756,104 | -- |
| 2026-07-27 | Michael Severino | Chief Executive Officer | Other Derivative Acquisition | +2,224,342 | $17.74 |
| 2026-06-03 | M. Behrens Wilsey | Independent Chairwoman | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Hans Wigzell | Chairman of Corporate Strategy Board & Independent Non-Employee Director | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Richard Barry | Independent Director | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Michael Chambers | Independent Director | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Deirdre Connelly | Director | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Stephen Mayo | Independent Director | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Claude Nicaise | Independent Director | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Kathryn Boor | Independent Director | Other Acquisition | +16,875 | -- |
| 2026-03-11 | Stephen Mayo | Independent Director | Open Market Disposition | -7,239 | $17.02 |
| 2026-03-10 | Louise Rodino-Klapac | Executive VP, Chief Scientific Officer and Head of Research & Development | Sale to Issuer | -948 | $17.03 |
| 2026-03-10 | Ian Estepan | Chief Financial Officer | Sale to Issuer | -1,097 | $17.03 |
| 2026-03-10 | Cristin Rothfuss | -- | Sale to Issuer | -974 | $17.03 |
| 2026-03-10 | Ryan Wong | Chief Financial Officer | Sale to Issuer | -256 | $17.03 |
| 2026-03-08 | Louise Rodino-Klapac | Executive VP, Chief Scientific Officer and Head of Research & Development | Sale to Issuer | -1,399 | $16.95 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
萨瑞普塔治疗 讨论区 0 条评论